REGENXBIO reported that its Duchenne muscular dystrophy gene therapy RGX‑202 has produced encouraging interim results in a Phase I/II study, with seven participants in the pivotal dose cohort showing functional gains that surpass external controls at one year.
The pivotal dose group, consisting of seven patients, achieved an average improvement of 4.9 points on the North Star Ambulatory Assessment (NSAA) and a 5.2‑point increase for the five patients aged 8 years or older, compared with the cTAP disease‑progression model. The data also include a microdystrophin expression level of 51.2 % in one patient at week 12, supporting the therapeutic mechanism.
Cardiac magnetic‑resonance imaging revealed stability in left ventricular ejection fraction, with a mean of 61.6 % at 12 months versus 61.7 % at baseline, and no changes in global circumferential strain. Safety data were favorable, with no serious adverse events or adverse events of special interest reported in the 13‑patient cohort.
Chief Medical Officer Steve Pakola said, 'Today's new Phase I/II interim data demonstrates continued positive impact on function, stable cardiac health, and a favorable safety profile, highlighting the potential of RGX‑202 to be a differentiated gene therapy option for Duchenne.' The company plans a pre‑BLA meeting with the FDA in mid‑2026 and intends to pursue an accelerated‑approval pathway based on the unmet medical need.
REGENXBIO’s full‑year 2025 results showed revenue of $170.4 million, up 102 % from $83.3 million in 2024, driven by collaboration and royalty income, while the net loss narrowed to $193.9 million from $227.1 million. Cash and cash equivalents stood at $240.9 million as of December 31 2025, providing a runway that extends into early 2027.
The company is also navigating class‑action securities litigation related to its RGX‑111 and RGX‑121 programs, which could influence investor sentiment, but the RGX‑202 data reinforce the pipeline’s commercial potential.
Topline data from the pivotal trial are expected in the second quarter of 2026, after which REGENXBIO will seek regulatory submission. The interim results strengthen the company’s position in the Duchenne market and support its broader strategy of expanding a portfolio of gene‑therapy products.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.